Search Result

Results for "

miR-17

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MicroRNA (25)
By Research Areas:	Cancer (23) Metabolic Disease (3)
Oligonucleotides:	miRNA mimics (5) miRNA antagomirs (5) miRNA agomirs (5) MicroRNAs (20) miRNA inhibitors (5) Antisense Oligonucleotides (4)

Inhibitors & Agonists

Oligonucleotides

Targets Recommended: MicroRNA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139290

RGLS4326 2 Publications Verification RG4326	MicroRNA	Metabolic Disease Cancer
RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of *microRNA-17* (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-150364A

Farabursen sodium RGLS8429 sodium; RG1015 sodium	MicroRNA	Metabolic Disease
Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a *miR-17* inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease .

HY-150364

Farabursen RGLS8429; RG1015	MicroRNA	Metabolic Disease
Farabursen (RGLS8429; RG1015) is a blood-brain barrier-permeable *miR-17* inhibitor. Farabursen derepresses Pkd1 and Pkd2, the target genes of miR-17, increases the levels of PC1 and PC2, and reduces cyst growth. Farabursen decreases renal cyst growth, kidney weight-to-body weight ratio, cyst index, proliferation index, and blood urea nitrogen levels in mouse models. Farabursen is applicable to research related to autosomal dominant polycystic kidney disease .

HY-139290A

RGLS4326 sodium 2 Publications Verification RG4326 sodium	MicroRNA	Cancer
RGLS4326 sodium is a first-in-class, short oligonucleotide inhibitor of *microRNA-17* (miR-17). RGLS4326 sodium can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 sodium inhibits miR-17 function in HeLa cells with an EC₅₀ value of 28.3 nM .

HY-R00326

*hsa-miR-17-5p mimic*	MicroRNA	Cancer
hsa-miR-17-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-17-5p mimic hsa-miR-17-5p mimic

HY-RI00326

*hsa-miR-17-5p inhibitor*	MicroRNA	Cancer
hsa-miR-17-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-17-5p inhibitor hsa-miR-17-5p inhibitor

HY-RI00325

*hsa-miR-17-3p inhibitor*	MicroRNA	Cancer
hsa-miR-17-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-17-3p inhibitor hsa-miR-17-3p inhibitor

HY-RI00326A

*hsa-miR-17-5p antagomir*	MicroRNA	Cancer
hsa-miR-17-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-17-5p antagomir hsa-miR-17-5p antagomir

HY-R00326A

*hsa-miR-17-5p agomir*	MicroRNA	Cancer
hsa-miR-17-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-17-5p agomir hsa-miR-17-5p agomir

HY-R00325

*hsa-miR-17-3p mimic*	MicroRNA	Cancer
hsa-miR-17-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-17-3p mimic hsa-miR-17-3p mimic

HY-R02695

*mmu-miR-17-3p mimic*	MicroRNA	Cancer
mmu-miR-17-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-17-3p mimic mmu-miR-17-3p mimic

HY-R04250

*rno-miR-17-2-3p mimic*	MicroRNA	Cancer
rno-miR-17-2-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-17-2-3p mimic rno-miR-17-2-3p mimic

HY-RI02695

*mmu-miR-17-3p inhibitor*	MicroRNA	Cancer
mmu-miR-17-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-17-3p inhibitor mmu-miR-17-3p inhibitor

HY-RI04250

*rno-miR-17-2-3p inhibitor*	MicroRNA	Cancer
rno-miR-17-2-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-17-2-3p inhibitor rno-miR-17-2-3p inhibitor

HY-R04250A

*rno-miR-17-2-3p agomir*	MicroRNA	Cancer
rno-miR-17-2-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-17-2-3p agomir rno-miR-17-2-3p agomir

HY-RI00325A

*hsa-miR-17-3p antagomir*	MicroRNA	Cancer
hsa-miR-17-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-17-3p antagomir hsa-miR-17-3p antagomir

HY-R04249

*rno-miR-17-1-3p mimic*	MicroRNA	Cancer
rno-miR-17-1-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-17-1-3p mimic rno-miR-17-1-3p mimic

HY-RI04249

*rno-miR-17-1-3p inhibitor*	MicroRNA	Cancer
rno-miR-17-1-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-17-1-3p inhibitor rno-miR-17-1-3p inhibitor

HY-R02695A

*mmu-miR-17-3p agomir*	MicroRNA	Cancer
mmu-miR-17-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-17-3p agomir mmu-miR-17-3p agomir

HY-R00325A

*hsa-miR-17-3p agomir*	MicroRNA	Cancer
hsa-miR-17-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-17-3p agomir hsa-miR-17-3p agomir

HY-R04249A

*rno-miR-17-1-3p agomir*	MicroRNA	Cancer
rno-miR-17-1-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-17-1-3p agomir rno-miR-17-1-3p agomir

HY-RI02695A

*mmu-miR-17-3p antagomir*	MicroRNA	Cancer
mmu-miR-17-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-17-3p antagomir mmu-miR-17-3p antagomir

HY-RI04249A

*rno-miR-17-1-3p antagomir*	MicroRNA	Cancer
rno-miR-17-1-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-17-1-3p antagomir rno-miR-17-1-3p antagomir

HY-RI04250A

*rno-miR-17-2-3p antagomir*	MicroRNA	Cancer
rno-miR-17-2-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-17-2-3p antagomir rno-miR-17-2-3p antagomir

HY-179344

Benzazepinoquinoline-spermine	MicroRNA	Cancer
Benzazepinoquinoline-spermine (Compound PA-3) is an efficient pre-miR-372 complexing agent, and it can specifically inhibit its processing mediated by Dicer. Its IC₅₀ value is 0.58 μM. Benzazepinoquinoline-spermine has a strong affinity for pre-miR-372, with a K_D value of 0.11 μM. Benzazepinoquinoline-spermine also shows high activity against pre-miR-373 (IC₅₀ = 0.29 μM), but significantly reduced inhibitory activity against pre-miR-17, pre-miR-21, and pre-miR-155 (IC₅₀ being 0.84 μM, 1.43 μM, and 1.07 μM respectively). Benzazepinoquinoline-spermine can be used for cancer research .

Cat. No.	Product Name		Classification